Drug-carrier complex

In plasma, the drug-carrier complex is exposed to normal clearance mechanisms by the liver, the kidney, and the reticuloendothelial system. The success of avoiding these nonspecific clearance mechanisms depends on the affinity of carriers for their target receptors and on their plasma concentrations. An excess of conjugate in plasma caused by saturation of its cellular uptake by means of the target receptors renders the conjugate present in plasma more susceptible to nonspecific removal. 

Drug-carrier complexes may be antigenic for both T and B cells. Stimulation and proliferation of dmg-specific T cell clones (sensitization) may provide help for the generation of a separate, B cell immune response to the hapten-carrier compound. 

Restimulation of Primed T Cells by Drug-Carrier Complexes (Hapten Model)... 

Fig. 4.7 Some widely applicable chemical strategies for the preparation of drug-carrier complexes. From Baldo BA and Pham Nl I. Stmctiire-activity studies on...

---